WOONSOCKET – MultiCell Technologies Inc. has filed a second patent application for a cancer-fighting method and formula to achieve targeted tumor cell death.
A biopharmaceutical company that develops and tests novel treatments for liver cancer, multiple sclerosis and other diseases, MultiCell Technology has already patented a noncoding double stranded micro RNA (miRNA) called MCT-485, which stimulates immune activity in in vitro models of hepatocellular carcinoma, the most common form of liver cancer. MCT-485 is currently being tested in animal models and is the first in a series of prospective cancer therapeutics being developed by MultiCell Techonology.
The company’s more recent patent application covers a method and formula for directing MCT-485 and other miRNAs towards tumor cells and away from healthy tissue. Only those cells that have the highest capability to grow tumors would a cytotoxic dose of a biologically active agent under this method and formula, leaving tissue not directly involved in the cancer-forming process untouched.